or Try an Advanced Search...

    Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.33 8.25% 0.03
    MRNS closed up 8.25 percent on Friday, November 1, 2024, on 81 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Nov 5
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical MRNS trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Boomer Sell Setup Bearish Swing Setup 8.25%
    Calm After Storm Range Contraction 8.25%
    NR7 Range Contraction 8.25%
    NR7-2 Range Contraction 8.25%
    Narrow Range Bar Range Contraction 8.25%
    Older End-of-Day Signals for MRNS ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 23 hours ago
    Rose Above Previous Day's High about 23 hours ago
    Outside Day about 23 hours ago
    Up 5% about 23 hours ago
    Up 3% about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MRNS Chart by TradingView
    Basic chart:

    Profile

    Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Drugs Alcohol Neuroscience Ketones Seizure Sedatives Fragile X Syndrome Pregnanes Neurosteroids

    Is MRNS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 25 Marinus downgraded after setback to late-stage trial
    Oct 25 Marinus’ clinical trial of ganaxolone fails to meet primary endpoint
    Oct 25 GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar
    Oct 24 Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
    Oct 24 Marinus tanks after late stage trial for treatment of seizures in TSC fails to meet main goal
    Oct 24 Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
    Oct 18 Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment
    Oct 17 Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
    Oct 15 Health Care Roundup: Market Talk
    Oct 15 Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
    See more MRNS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 11.26
    52 Week Low 0.2603
    Average Volume 2,810,315
    200-Day Moving Average 3.74
    50-Day Moving Average 1.43
    20-Day Moving Average 1.26
    10-Day Moving Average 0.76
    Average True Range 0.16
    RSI (14) 23.66
    ADX 44.01
    +DI 11.00
    -DI 50.47
    Chandelier Exit (Long, 3 ATRs) 1.48
    Chandelier Exit (Short, 3 ATRs) 0.74
    Upper Bollinger Bands 2.63
    Lower Bollinger Band -0.11
    Percent B (%b) 0.16
    BandWidth 217.13
    MACD Line -0.36
    MACD Signal Line -0.21
    MACD Histogram -0.1465
    Fundamentals Value
    Market Cap 17.89 Million
    Num Shares 54.6 Million
    EPS -2.78
    Price-to-Earnings (P/E) Ratio -0.12
    Price-to-Sales 17.71
    Price-to-Book 10.10
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.38
    Resistance 3 (R3) 0.37 0.35 0.37
    Resistance 2 (R2) 0.35 0.34 0.35 0.37
    Resistance 1 (R1) 0.34 0.33 0.35 0.34 0.36
    Pivot Point 0.32 0.32 0.32 0.32 0.32
    Support 1 (S1) 0.31 0.31 0.31 0.31 0.29
    Support 2 (S2) 0.29 0.30 0.29 0.29
    Support 3 (S3) 0.28 0.29 0.29
    Support 4 (S4) 0.28